+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Branded Generics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Branded Generics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Branded Generics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 5896414
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Branded Generics Market grew from USD 494.29 billion in 2024 to USD 567.75 billion in 2025. It is expected to continue growing at a CAGR of 14.74%, reaching USD 1.12 trillion by 2030.

The branded generics segment occupies a critical juncture where innovation meets affordability. As patent cliffs widen and healthcare budgets tighten, pharmaceutical companies are increasingly leveraging branded generics to sustain revenue streams while delivering cost-effective therapies. This executive summary distills the essential insights needed to navigate this evolving space. It outlines the pivotal market forces at play, scrutinizes regulatory headwinds such as new United States tariffs, deciphers nuanced segmentation dynamics, and maps regional growth vectors. By combining industry intelligence with strategic analysis, this document equips decision-makers with a clear understanding of the current environment and the actionable strategies needed to capitalize on emerging opportunities. Whether your focus centers on expanding product portfolios, optimizing supply chains, or shaping competitive positioning, the insights presented here serve as a compass for the complex branded generics ecosystem.

Transformative Shifts Redefining the Branded Generics Landscape

The branded generics landscape is undergoing transformative shifts driven by a convergence of technological innovation, regulatory realignment, and evolving patient expectations. Rapid advancements in manufacturing processes, from continuous flow chemistry to digital batch monitoring, are enabling producers to scale high-quality generics more efficiently than ever before. Simultaneously, an increased emphasis on pharmacovigilance and quality standards is reshaping regulatory frameworks, prompting companies to adopt robust compliance infrastructures. As health systems worldwide demand greater cost-containment, payers are negotiating more aggressive pricing agreements, forcing manufacturers to rethink product positioning and lifecycle management. Moreover, the rise of telemedicine and digital health platforms is altering distribution channels, accelerating direct-to-patient engagement and fostering new partnership models between drugmakers and technology firms. In this environment, sustainable supply chain practices and transparent ESG reporting have emerged as competitive differentiators, compelling branded generics companies to integrate environmental and social governance into their core strategies. These converging trends are redefining how market participants approach research, development, and commercialization.

Cumulative Impact of United States Tariffs in 2025 on Branded Generics

In 2025, newly imposed United States tariffs have exerted a cumulative impact across the branded generics value chain. Raw material costs have surged, particularly for active pharmaceutical ingredients sourced from international suppliers, squeezing margins and prompting manufacturers to explore alternative sourcing strategies. The increased import duties have translated into higher average selling prices for certain branded generics, reshaping reimbursement negotiations and placing additional pressure on payers. In response, several stakeholders have implemented dual-sourcing protocols to mitigate supply risk while leveraging regional manufacturing hubs to offset tariff exposure. Logistics costs have also climbed, driving investment in nearshoring and cross-border distribution centers closer to key demand markets. These adaptive measures are reshaping cost structures, accelerating consolidation among mid-tier players unable to absorb margin compression, and reinforcing the need for agile pricing models. Despite these headwinds, companies that preemptively revised their supply network design and optimized cost-to-serve frameworks have preserved profitability and maintained continuity of patient access.

Key Segmentation Insights Driving Branded Generics Performance

Branded generics performance varies significantly across dosage forms, disease categories, and market access channels. Capsule, tablet, oral solution liquids, and topical forms each exhibit distinct manufacturing complexities and margin profiles, while inhalers-both dry powder and metered dose-and injectables, including ampoules, pre-filled syringes, and vials (liquid and lyophilized powder), demand specialized capabilities and stringent cold-chain management. The therapeutic focus on both acute conditions such as infections and injuries and chronic indications including chronic pain, diabetes, and hypertension highlights divergent development timelines and clinical trial requirements. Gender-specific demand patterns underscore minor differences in prescribing behaviors between female and male patients, yet distribution through ambulatory surgery centers, clinics, hospitals, online pharmacies, and retail outlets-spanning both chain and independent pharmacies-introduces nuanced reimbursement and promotional strategies. Prescription type segmentation divides the market between over-the-counter and prescription medicines, affecting marketing spend and regulatory pathways. Prescriber dynamics, from primary healthcare providers like clinics and family physicians to specialists including cardiologists, dermatologists, and endocrinologists, shape detailing efforts. Finally, choices between chemical entities and therapeutic groups, rapid versus sustained release-with extended duration and late onset formats-alongside brand positioning metrics centered on loyalty, market share, and sales revenue, collectively define product life cycles and growth potential.

Regional Dynamics Shaping Branded Generics Growth Worldwide

Regional dynamics play a pivotal role in shaping branded generics growth. In the Americas, robust healthcare infrastructure and mature reimbursement systems foster high uptake of lower-cost alternatives, though pricing pressures from consolidated payers challenge manufacturers to demonstrate value beyond unit cost. Europe, Middle East & Africa present a heterogeneous landscape: Western Europe’s tender-driven procurement and centralized pricing negotiate down margins, whereas emerging markets in the Middle East and Africa seek affordable therapies to broaden access, stimulating partnerships between global players and local producers. In Asia-Pacific, varying stages of regulatory maturity-from stringent standards in Japan and Australia to expedited approvals in Southeast Asia-create both hurdles and rapid-launch opportunities. Market participants are investing in localized production and forging alliances with regional distributors to navigate diverse regulatory requirements and optimize supply chains. Understanding these three macro regions is critical for calibrating go-to-market strategies, aligning pricing models with payer expectations, and prioritizing market entry based on competitive intensity and growth outlook.

Competitive Landscape: Key Company Strategies and Positioning

The competitive landscape features a blend of global pharmaceutical giants and specialized generics manufacturers. Industry leaders such as Abbott Laboratories, Pfizer Inc., and Sanofi S.A. leverage extensive R&D resources and established brand portfolios to cross-subsidize lower-margin generics products. Companies like Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., and Cipla Limited focus on cost-efficient production and aggressive market expansion in emerging geographies, while Sandoz International GmbH by Novartis AG and Teva Pharmaceutical Industries Ltd. capitalize on scale to optimize distribution networks. Emerging players, including Ajanta Pharma Ltd. and Torrent Pharmaceuticals Ltd., differentiate through niche therapy segments and patient-centric programs. Their strategies encompass strategic acquisitions, joint ventures with local distributors, and targeted investments in biosimilars and complex generics such as inhalers and injectables. Specialty-focused firms like Amneal Pharmaceuticals LLC and Lupin Limited are also forging alliances with primary healthcare networks and hospitals to enhance market penetration. As consolidation accelerates, mid-tier entities face pressure to innovate service offerings or align with bigger organizations to remain competitive.

Actionable Recommendations for Industry Leaders in Branded Generics

To thrive amid intensifying competition and regulatory complexity, industry leaders should pursue several strategic imperatives. First, integrating digital manufacturing platforms with predictive analytics can enhance batch yield, shorten time-to-market, and strengthen quality assurance. Second, diversifying portfolios through biosimilars and value-added formulations-particularly in inhalers, injectables, and sustained-release categories-can unlock new revenue streams and foster payer engagement. Third, establishing resilient, multi-regional supply chains with nearshoring capabilities will mitigate tariff risks and bolster business continuity. Fourth, deepening collaborations with prescribers-ranging from primary care clinics to specialists in cardiology, dermatology, and endocrinology-through educational initiatives and real-world evidence sharing will reinforce brand loyalty. Fifth, adopting flexible pricing strategies that align with localized reimbursement frameworks in the Americas, EMEA, and Asia-Pacific will maintain competitive positioning. Finally, embedding ESG principles into operational and governance models will enhance corporate reputation and meet stakeholder expectations in sustainability reporting.

Executive Summary: Concluding Perspectives on Branded Generics

This executive summary has illuminated the critical forces reshaping the branded generics sector: from the pressure of new United States tariffs and the proliferation of digital health platforms to the intricate segmentation of dosage forms, disease areas, and distribution channels. Regional disparities in regulatory rigor and market maturity underscore the necessity of tailored go-to-market approaches, while the evolving competitive landscape demands continuous innovation in manufacturing, portfolio mix, and strategic partnerships. By synthesizing these insights, industry stakeholders can formulate robust strategies that enhance operational resilience, accelerate market entry, and drive sustainable growth. The conclusions drawn here provide a framework for navigating uncertainty, aligning organizational capabilities with market demands, and seizing the untapped potential within the branded generics arena.

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Capsule
  • Inhalers
    • Dry Powder Inhalers
    • Metered Dose Inhalers
  • Injectables
    • Ampoules
    • Pre-Filled Syringes
    • Vials
      • Liquid Vials
      • Lyophilized Powder Vials
  • Oral Solution Liquids
  • Tablet
  • Topical
  • Acute Diseases
    • Infections
    • Injuries
  • Chronic Diseases
    • Chronic Pain
    • Diabetes
    • Hypertension
  • Female
  • Male
  • Ambulatory Surgery Centers
  • Clinics
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
    • Chain Pharmacies
    • Independent Pharmacies
  • Over-The-Counter Medicine
  • Prescription Medicine
  • Primary Healthcare Providers
    • Clinics
    • Family Physicians
  • Specialists
    • Cardiologists
    • Dermatologists
    • Endocrinologists
  • Chemical Entity
  • Therapeutic Group
  • Rapid Release
  • Sustained Release
    • Extended Duration
    • Late Onset
  • Brand Loyalty
  • Market Share
  • Sales Revenue

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Branded Generics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Ajanta Pharma Ltd.
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Endo International PLC
  • Eris Lifesciences Limited
  • Eva Pharma
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs Limited
  • Lupin Limited
  • Micro Labs Limited
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zentiva Group, a.s.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Branded Generics Market, by Dosage Form
8.1. Introduction
8.2. Capsule
8.3. Inhalers
8.3.1. Dry Powder Inhalers
8.3.2. Metered Dose Inhalers
8.4. Injectables
8.4.1. Ampoules
8.4.2. Pre-Filled Syringes
8.4.3. Vials
8.4.3.1. Liquid Vials
8.4.3.2. Lyophilized Powder Vials
8.5. Oral Solution Liquids
8.6. Tablet
8.7. Topical
9. Branded Generics Market, by Diseases Treated
9.1. Introduction
9.2. Acute Diseases
9.2.1. Infections
9.2.2. Injuries
9.3. Chronic Diseases
9.3.1. Chronic Pain
9.3.2. Diabetes
9.3.3. Hypertension
10. Branded Generics Market, by Gender
10.1. Introduction
10.2. Female
10.3. Male
11. Branded Generics Market, by Distribution Channel
11.1. Introduction
11.2. Ambulatory Surgery Centers
11.3. Clinics
11.4. Hospitals
11.5. Online Pharmacies
11.6. Retail Pharmacies
11.6.1. Chain Pharmacies
11.6.2. Independent Pharmacies
12. Branded Generics Market, by Prescription Type
12.1. Introduction
12.2. Over-The-Counter Medicine
12.3. Prescription Medicine
13. Branded Generics Market, by Prescriber Type
13.1. Introduction
13.2. Primary Healthcare Providers
13.2.1. Clinics
13.2.2. Family Physicians
13.3. Specialists
13.3.1. Cardiologists
13.3.2. Dermatologists
13.3.3. Endocrinologists
14. Branded Generics Market, by Substance Group
14.1. Introduction
14.2. Chemical Entity
14.3. Therapeutic Group
15. Branded Generics Market, by Release Type
15.1. Introduction
15.2. Rapid Release
15.3. Sustained Release
15.3.1. Extended Duration
15.3.2. Late Onset
16. Branded Generics Market, by Brand Positioning
16.1. Introduction
16.2. Brand Loyalty
16.3. Market Share
16.4. Sales Revenue
17. Americas Branded Generics Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Branded Generics Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Branded Generics Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Abbott Laboratories
20.3.2. Ajanta Pharma Ltd.
20.3.3. Alkem Laboratories Ltd.
20.3.4. Amneal Pharmaceuticals LLC
20.3.5. Apotex Inc.
20.3.6. Aspen Pharmacare Holdings Limited
20.3.7. AstraZeneca PLC
20.3.8. Aurobindo Pharma Limited
20.3.9. Bausch Health Companies Inc.
20.3.10. Bristol-Myers Squibb Company
20.3.11. Cipla Limited
20.3.12. Dr. Reddy’s Laboratories Ltd.
20.3.13. Endo International PLC
20.3.14. Eris Lifesciences Limited
20.3.15. Eva Pharma
20.3.16. Fresenius Kabi AG
20.3.17. GlaxoSmithKline PLC
20.3.18. Glenmark Pharmaceuticals Limited
20.3.19. Hetero Drugs Limited
20.3.20. Lupin Limited
20.3.21. Micro Labs Limited
20.3.22. Nichi-Iko Pharmaceutical Co., Ltd.
20.3.23. Pfizer Inc.
20.3.24. Sandoz International GmbH by Novartis AG
20.3.25. Sanofi S.A.
20.3.26. Sun Pharmaceutical Industries Ltd.
20.3.27. Teva Pharmaceutical Industries Ltd.
20.3.28. Torrent Pharmaceuticals Ltd.
20.3.29. Viatris Inc.
20.3.30. Zentiva Group, a.s.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. BRANDED GENERICS MARKET MULTI-CURRENCY
FIGURE 2. BRANDED GENERICS MARKET MULTI-LANGUAGE
FIGURE 3. BRANDED GENERICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY AMPOULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIQUID VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY LYOPHILIZED POWDER VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL SOLUTION LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJURIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRANDED GENERICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRANDED GENERICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY OVER-THE-COUNTER MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BRANDED GENERICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BRANDED GENERICS MARKET SIZE, BY FAMILY PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOLOGISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BRANDED GENERICS MARKET SIZE, BY ENDOCRINOLOGISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHEMICAL ENTITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BRANDED GENERICS MARKET SIZE, BY RAPID RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BRANDED GENERICS MARKET SIZE, BY EXTENDED DURATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BRANDED GENERICS MARKET SIZE, BY LATE ONSET, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BRANDED GENERICS MARKET SIZE, BY BRAND LOYALTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BRANDED GENERICS MARKET SIZE, BY MARKET SHARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BRANDED GENERICS MARKET SIZE, BY SALES REVENUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 126. CANADA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 127. CANADA BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 128. CANADA BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 129. CANADA BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 130. CANADA BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 131. CANADA BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 132. CANADA BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 133. CANADA BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 134. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. CANADA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 136. CANADA BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 137. CANADA BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 138. CANADA BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 139. CANADA BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 140. CANADA BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 141. CANADA BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 142. CANADA BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 143. CANADA BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 218. CHINA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 219. CHINA BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 220. CHINA BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 221. CHINA BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 222. CHINA BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 223. CHINA BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 224. CHINA BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 225. CHINA BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 226. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. CHINA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 228. CHINA BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 229. CHINA BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 230. CHINA BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 231. CHINA BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 232. CHINA BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 233. CHINA BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 234. CHINA BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 235. CHINA BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 236. INDIA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 237. INDIA BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 238. INDIA BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 239. INDIA BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 240. INDIA BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 241. INDIA BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 242. INDIA BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 243. INDIA BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 244. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. INDIA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. INDIA BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDIA BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 248. INDIA BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 249. INDIA BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 250. INDIA BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 251. INDIA BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 252. INDIA BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 253. INDIA BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 272. JAPAN BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 273. JAPAN BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 274. JAPAN BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 275. JAPAN BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 276. JAPAN BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 277. JAPAN BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 278. JAPAN BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 279. JAPAN BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 280. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. JAPAN BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 282. JAPAN BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 283. JAPAN BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 284. JAPAN BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 285. JAPAN BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 286. JAPAN BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 287. JAPAN BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 288. JAPAN BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 289. JAPAN BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 308. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 310. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 311. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 316. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 318. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 319. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 320. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 321. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 322. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 323. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 324. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 325. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 326. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 327. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 328. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 329. SINGAPORE BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 330. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 331. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 332. SINGAPORE BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 333. SINGAPORE BRANDED GENERICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 334. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. SINGAPORE BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 336. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 337. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRESCRIBER TYPE, 2018-2030 (USD MILLION)
TABLE 338. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRIMARY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 339. SINGAPORE BRANDED GENERICS MARKET SIZE, BY SPECIALISTS, 2018-2030 (USD MILLION)
TABLE 340. SINGAPORE BRANDED GENERICS MARKET SIZE, BY SUBSTANCE GROUP, 2018-2030 (USD MILLION)
TABLE 341. SINGAPORE BRANDED GENERICS MARKET SIZE, BY RELEASE TYPE, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE BRANDED GENERICS MARKET SIZE, BY SUSTAINED RELEASE, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE BRANDED GENERICS MARKET SIZE, BY BRAND POSITIONING, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY VIALS, 2018-2030 (USD MILLION)
TABLE 348. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
TABLE 349. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ACUTE DISEASES, 2018-2030 (USD MILLION)
TABLE 350. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY CHRONIC DISEASES, 2018-

Companies Mentioned

  • Abbott Laboratories
  • Ajanta Pharma Ltd.
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Endo International PLC
  • Eris Lifesciences Limited
  • Eva Pharma
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs Limited
  • Lupin Limited
  • Micro Labs Limited
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zentiva Group, a.s.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Branded Generics - Global Strategic Business Report - Product Image

Branded Generics - Global Strategic Business Report

  • Report
  • 354 Pages
  • Global
From
Branded Generics Market Report 2025 - Product Image

Branded Generics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 190 Pages
  • Global
From
2025 Global Forecast for Branded Generics (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Branded Generics (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From

About the Branded Generics Market

Branded generics are generic drugs that are marketed under a brand name. They are typically manufactured by a generic drug company, but are sold under a brand name owned by a pharmaceutical company. Branded generics are typically sold at a higher price than generic drugs, but are still much cheaper than the original brand-name drug. They are often used to increase the market share of a generic drug company, as well as to increase the visibility of a generic drug in the marketplace. Branded generics are becoming increasingly popular in the pharmaceutical industry, as they offer a cost-effective alternative to brand-name drugs. They are also used to increase the market share of generic drug companies, as well as to increase the visibility of generic drugs in the marketplace. Some companies in the branded generics market include Teva Pharmaceuticals, Mylan, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.